Summary Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) 
Aminoglutethimide (AG), in a dose of 1 g daily combined with hydrocortisone (HC), is effective in the treatment of advanced postmenopausal breast cancer (Smith et al., 1978; Harris et al., 1982) ; Santen et al., 1982) and has been assumed to act as a "medical adrenalectomy". Adrenal suppression is achieved principally through inhibition of the desmolase enzyme system (Kahnt & Neher, 1966; responsible for the conversion of cholesterol to pregnenolone. However, AG also inhibits the peripheral aromatase enzyme system (Graves & Salhanick, 1979; Brodie, 1982; Santen et al., 1978) , believed to be the major source of oestrone synthesis in postmenopausal women (MacDonald et al., 1967; Grodin et al., 1973) .
In vitro studies suggest that aromatase inhibition is achieved by lower doses of AG than necessary for desmolase inhibition (Graves & Salhanick, 1979; Santen & Misbin, 1981; Harris et al., 1983) and thus, aromatase inhibition rather than adrenal suppression may be the underlying mechanism of oestrogen suppression by AG. For this reason, and as the side effects of AG have been reported to be dose-related (Murray et al., 1979) , several investigators have recently assessed the use of low dose AG, without a glucocorticoid as a method of ostrogen suppression (Stuart-Harris et al., 1985; Harris et al., 1983; Vermeulen et al., 1983) .
© The Macmillan Press Ltd., 1985 To date, there are only limited data concerning the metabolism and pharmacokinetics of AG. After oral administration of 0.1-I.Og of AG, 35-54% of the dose is excreted unchanged in the urine within 48 hours (Douglas & Nicholls, 1965 , 1972 . Nacetylaminoglutethimide (NAG) has been identified as the major metabolite, and 4-25% of an oral dose of AG is excreted as urinary NAG within 48 h. Acetylation is phenotype dependent with significantly higher levels of NAG achieved by fast acetylators (Coombes et al., 1980) . Peak plasma AG levels of 5.6-6.3 4ugml-1 have been observed 0.7-1.5h after 500mg AG given to healthy volunteers (Thompson et al., 1981) : an initially rapid decline in plasma concentration of the drug occurs, followed by a slower decline with a half-life of 10-15 h.
Although serum levels of AG have been examined in postmenopausal breast cancer patients receiving conventional doses of AG combined with HC (Murray et al., 1979) , there has been no previous study of drug levels during conventional dose AG without HC, or during low dose AG therapy alone with or without HC.
Materials and methods

Patients
After approval from the Medical Ethics Committee of the Royal Marsden Hospital and informed patient consent, 33 postmenopausal women with advanced breast cancer participated in the study. All were more than two years from their last menstrual period; mean age was 64 years (range 
Measurement of AG and NAG levels
Serum AG and NAG levels were measured by high pressure liquid chromatography, the method for which is described fully elsewhere (Adam et al., 1984) . Briefly, a 30cm by 4mm reversed-phase Lichrosorb column (5 gm, RP8) with a mobile phase of 42:58 methanol/water at a flow rate of 0.9 ml min-1 were used. Serum samples were thawed and after thorough mixing, 0.5ml pipetted into 1Oml stoppered glass centrifuge tubes. Fifteen jl internal standard (l00yjgml-' phenacetin in methanol), 0.5 ml of acetate buffer (pH 6.0), and 3 ml of dichloromethane were then added to the samples which were extracted on a rollermixer for 15min.
Following centrifugation for 5 min, the upper aqueous layer was carefully removed and discarded while the lower organic layer was transferred to a further centrifuge tube and evaporated in a water bath at 400C under a stream of nitrogen. The residue was dissolved in 120jl of the mobile phase and 20 pl taken and injected into the chromatograph.
Serum samples containing known concentrations of AG and NAG were treated in a similar manner and a standard curve prepared by plotting the peak height of drug against internal standard concentration. The inter-assay coefficient of variation for AG was 14.3% at ljigml-P, 9.1% at 3jigml-P and 6.9% at 8 jg ml-1 and for NAG 8.3% at 0.5ugml-1, 4.4% at 2.0 pgml -' and 4.8% at 4.0/,tgml-'. The intra-assay coefficient of variation for AG was 2.5% at 2ugml', 2.7% at 5pgml-1 and 10.5% at 10igml-1 and for NAG 1.9% at 0.5pgml-', 1.0% at lugml-' and 0.7% at 3 jug ml -'.
Analysis of data Because of variation in the time intervals between drug administration and blood sampling, data were selected so that the only samples described in this report were those for which the interval between dose and blood collection was +1 hour of the usual interval for each patient. With this selection, data were available for 24 of 33 patients..
Statistical analysis Serum concentrations of AG and NAG at the different doses were compared using paired t-tests, adjusted with the Bomferroni correction for multiple comparisons (Cupples et al., 1984) . Linear regression analysis (Dixon, 1981) was used to compare the concentrations of AG and NAG at each dosage.
Results
Serum AG and NAG concentrations and the resultant NAG:AG ratios at each dosage are shown in Tables I, II and III, respectively. Mean serum AG and NAG concentrations plotted against dose are shown in Figures 1 and 2 . The time intervals between drug administration and blood samples are shown in Table IV .
Statistical analysis using paired t-tests revealed that each dose increment was accompanied by a significant rise in both AG and NAG concentrations (P<0.05). However no significant alteration in AG or NAG concentration occurred when HC was added to the dose of 500mg b.d. of AG. Both AG and NAG concentrations appeared to increase in approximate linear relationships with dose (r = 0.982 and 0.948, Figures 1 and 2 respectively) . Linear regression analysis revealed that the regression lines for AG and NAG at the various dose levels (Figures 1 and 2 , respectively) were significantly different (P <0.0001). NAG concentrations increased significantly more slowly than AG, leading to a decline in the NAG:AG ratio observed at higher doses (Table III) . Although sequential dose increments were not accompanied by a significant fall in NAG:AG ratios, the ratios at the dose of 500mg b.d. of AG plus HC were significantly lower than at 62.5mg b.d. of AG (P=0.003, paired t-test). To investigate whether the NAG:AG ratio stabilised during more prolonged therapy, ratios were calculated for 15 of the patients who received treatment for more than four months duration (Table V) . Although this analysis suggested that the ratio stabilised only after six months of treatment, alterations in the NAG:AG ratio failed to achieve statistical significance using paired t-tests.
Discussion
There has been only one previous study which has investigated the serum drug levels in postmenopausal patients with advanced breast cancer (Murray et al., 1979) . This study, using a nonspecific spectrophotometric method noted that the mean serum AG concentration in seven patients after 12 weeks of AG (1 g daily) combined with HC (40mg daily) was 11.5+3.6pgml-' (mean+s.e.).
Although time intervals between dose and blood samples were not measured accurately, most samples were taken 2h after drug administration. Half-life and clearance rate studies performed in a further 6 patients at the start of therapy and later after 6 weeks of treatment demonstrated that the half-life of AG was shortened significantly and clearance rate increased significantly after 6 weeks of treatment. These data were interpreted as suggesting that AG, like glutethimide, may stimulate its own metabolism through hepatic microsomal enzyme induction (Jackson et al., 1978 ).
In the current study, the mean serum AG concentration in 24 patients receiving an identical dose Murray et al. (1979) . Murray et al. (1979) also suggested that AG can induce its own metabolism and that induction is probably complete within one week of starting therapy. Our observations that serum AG concentrations increased in an approximate linear relationship with increasing dose suggest that if induction occurs then this is completed within the first month of therapy. However, NAG concentrations increased significantly more slowly, leading to a fall in the NAG:AG ratio during therapy, although the ratio appeared to stabilise after approximately six months of therapy. The fall in the NAG:AG ratio during chronic therapy suggests that alteration in the metabolism of NAG may occur during prolonged treatment. The cause of this alteration is not known, but it may be that the production of NAG is rate-limited. The metabolism of other compounds, that are acetylated, such as isoniazid, has been shown to be rate-limited (Thom et al., 1981) . Recently however, a novel metabolite of AG, hydroxylaminoglutethmide (hydroxyl-AG), has been described (Jarman et al., 1983) . This report suggested that hydroxyl-AG may be an induced metabolite as it is only formed during chronic therapy. Moreover, the data suggested that hydroxyl-AG may be formed at the expense of NAG. It is possible therefore, that the fall in the NAG:AG 
